ReShape Lifesciences Inc. (RSLS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, ReShape Lifesciences reported revenue of $319,714, down 96.0% from $8.0M the year before. Net income was -$10.3M (a -3209.7% net margin), or -$4.86 per diluted share. Gross margin was 68.4% and operating margin was -3269.4%. Operating activities generated -$3.7M of cash. At fiscal year end, ReShape Lifesciences held $6.5M in total assets against $2.7M in total liabilities, including $5.0M of cash and equivalents.
Open the full interactive ReShape Lifesciences financials → Quarterly statements, key ratios, valuation history and price charts.
ReShape Lifesciences Key Stats
| Share Price | $1.97 |
|---|---|
| Market Cap | $13.8M |
| Revenue YoY Growth | -96.0% |
| 52-Week Range | $1.89 – $6.31 |
| Shares Outstanding | 7.0 million (basic, 2026 Q2) |
ReShape Lifesciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | $13.6M | $11.2M | $8.7M | $8.0M | $319,714 |
| Cost of Goods Sold | $1.0M | $5.3M | $4.4M | $3.1M | $2.9M | $100,943 |
| Gross Profit | $584,000 | $8.3M | $6.8M | $5.5M | $5.1M | $218,771 |
| Operating Income | -$12.0M | -$56.5M | -$46.4M | -$15.4M | -$7.7M | -$10.5M |
| Pre-Tax Income | -$12.3M | -$62.0M | -$46.6M | -$11.3M | -$7.1M | -$10.3M |
| Income Tax | $0 | -$106,000 | -$380,000 | $52,000 | $39,000 | — |
| Net Income | -$12.3M | -$61.9M | -$46.2M | -$11.4M | -$7.1M | -$10.3M |
| Diluted EPS | -$461100.00 | -$1450000.00 | -$631620.00 | -$11078.00 | -$1383.00 | -$4.86 |
ReShape Lifesciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $34,627 | — | $31,591 | $26,955 |
| Net Income | -$8.4M | -$672,196 | -$962,910 | -$685,556 |
| Diluted EPS | -$3.12 | -$0.31 | -$0.15 | -$0.10 |
ReShape Lifesciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.9M | $22.8M | $3.9M | $4.5M | $693,000 | $5.0M |
| Current Assets | $7.8M | $30.3M | $9.9M | $10.3M | $4.6M | $5.4M |
| Total Assets | $10.6M | $54.3M | $11.1M | $10.7M | $4.8M | $6.5M |
| Current Liabilities | $5.0M | $7.3M | $7.5M | $3.8M | $5.0M | $2.7M |
| Total Long-Term Debt | $430,000 | — | — | — | — | — |
| Total Liabilities | $6.0M | $8.2M | $7.5M | $4.0M | $5.0M | $2.7M |
| Shareholders' Equity | $4.7M | $46.1M | $3.7M | $6.7M | -$253,000 | $3.8M |
ReShape Lifesciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.4M | -$15.4M | -$21.9M | -$17.0M | -$4.4M | -$3.7M |
| Cash From Investing | -$171,000 | $1.9M | -$92,000 | -$10,000 | — | — |
| Cash From Financing | $430,000 | $33.3M | $3.1M | $17.6M | $677,000 | $8.7M |
| Free Cash Flow | -$10.6M | — | -$22.0M | -$17.0M | -$4.5M | — |
Figures from ReShape Lifesciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full ReShape Lifesciences financials page for every line item.
ReShape Lifesciences Company Profile
| Ticker | RSLS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Clemente, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001427570 |
Frequently Asked Questions
What was ReShape Lifesciences' revenue in fiscal 2025?
ReShape Lifesciences (RSLS) reported revenue of $319,714 for fiscal 2025.
What is ReShape Lifesciences' annual revenue history?
ReShape Lifesciences' annual revenue by fiscal year: 2020: $1.6M; 2021: $13.6M; 2022: $11.2M; 2023: $8.7M; 2024: $8.0M; 2025: $319,714.
What was ReShape Lifesciences' net income in fiscal 2025?
ReShape Lifesciences reported net income of -$10.3M for fiscal 2025.
What was ReShape Lifesciences' earnings per share (EPS) in fiscal 2025?
ReShape Lifesciences' diluted EPS was -$4.86 for fiscal 2025 (adjusted for any later stock splits).
What was ReShape Lifesciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), ReShape Lifesciences reported revenue of $26,955.
How many shares of ReShape Lifesciences are outstanding?
ReShape Lifesciences reported a weighted average of 7.0 million basic shares outstanding in 2026 Q2.
What is ReShape Lifesciences' market cap?
Based on its latest closing price, ReShape Lifesciences (RSLS) has a market capitalization of about $13.8M.
When does ReShape Lifesciences' fiscal year end?
ReShape Lifesciences' fiscal year end, as registered with the SEC, is December 31.
Where is ReShape Lifesciences headquartered?
ReShape Lifesciences lists its business address in San Clemente, California in its SEC filings.